Key Highlights

  • Loss per share was USD 0.54 against an estimated USD 0.67 loss, and the company reported no revenue.
  • Net loss was USD 25.1 million against USD 14.2 million, and Research and Development expense was USD 18.2 million.
  • Cash, cash equivalents and restricted cash were USD 319.8 million, up from USD 177.0 million at the end of 2025.
  • The filing describes a putative securities class action and a derivative action, and the company states the claims lack merit.

Alto Neuroscience (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on psychiatric disorders, reported a third quarter 2026 loss of USD 0.54 per share against an estimated loss of USD 0.67. The company reported no revenue, in line with the estimate. Net loss was USD 25.1 million against USD 14.2 million a year earlier, and USD 79.0 million for the nine months against USD 47.1 million.

Research and development expense was USD 18.2 million against USD 10.5 million, and general and administrative expense was USD 9.1 million against USD 4.4 million. The filing attributes about USD 6.9 million of the research increase to development of ALTO-207, which the company acquired in May 2025.

ALTO-207 and Pipeline Timing

ALTO-207 is a fixed-dose combination of pramipexole and ondansetron for treatment resistant depression. The Phase 2b trial began in April 2026, enrolls about 178 adults as an adjunctive treatment, and could serve as a pivotal trial subject to FDA feedback. The filing states the company plans topline data in the second half of 2027 and is preparing an adjunctive Phase 3 trial by early 2027, with a monotherapy Phase 3 trial planned for the second half of 2027.

The company is also running a Phase 2b trial of ALTO-300, also known as agomelatine, in major depressive disorder characterized by an EEG biomarker signature.

Cash and Funding

Cash, cash equivalents and restricted cash were USD 319.8 million at September 30, 2026, against USD 177.0 million at December 31, 2025, and the accumulated Deficit was USD 280.6 million. The filing also describes a convertible Loan agreement with the Wellcome Trust of up to about USD 11.7 million, with proceeds restricted to advancing ALTO-100 in bipolar depression.

Legal Disclosure and Items to Follow

The filing's commitments and contingencies note describes a putative class action filed July 21, 2025 in the United States District Court for the Northern District of California against the company, certain executive officers and certain current and former directors. It alleges violations of the Securities Act and Exchange Act related to the company's February 2024 IPO and later disclosures about ALTO-100. The filing states the company believes the allegations lack merit, that its motion to dismiss the second amended complaint was granted with leave to amend, and that a motion to dismiss the third amended complaint was filed September 11, 2026.

A consolidated stockholder derivative action, filed on behalf of the company on the same factual allegations, has been stayed since January 14, 2026. The company has not recorded a liability. These matters are reported as stated in the filing and are flagged for human legal review. The items to follow are the court's ruling, trial enrollment and the cash balance.